問卷

TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Division of Radiation Therapy

Division of General Internal Medicine

Digestive System Department

Division of Radiology

Division of General Surgery

更新時間:2023-09-19

謝佳訓Hsieh, Chia-Hsun
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 10 個月
  • wisdom5000@cgmh.org.tw

篩選

List

159Cases

2021-11-01 - 2027-03-20

Phase I/II

Active
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors
  • Condition/Disease

    Advanced MTAP-null Solid Tumors

  • Test Drug

    錠劑

Participate Sites
4Sites

Recruiting4Sites

2017-11-01 - 2021-05-20

Phase III

Completed
A Randomized, Open-label, Multi-center Phase 3 study to Compare the efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in patients with Unresectable Hepatocellular Carcinoma
  • Condition/Disease

    unresectable HCC

  • Test Drug

    Tislelizumab

Participate Sites
11Sites

Terminated9Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2025-02-20 - 2027-10-29

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2026-06-01 - 2030-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting9Sites

2025-11-01 - 2027-08-22

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2014-04-01 - 2017-01-01

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2016-05-01 - 2020-12-31

Phase II

Completed
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer.
  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    Merestinib and Ramucirumab

Participate Sites
6Sites

Terminated5Sites

2025-10-01 - 2027-09-30

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2015-09-15 - 2019-09-30

Phase III

Completed
A Multicenter, Randomized, Open-label Study in Patients with esophageal Cancer refractory or intolerant to Combination Therapy with Fluoropyrimidine and Platinum-based Drugs
  • Condition/Disease

    Esophageal cancer

  • Test Drug

    ONO-4538 (Nivolumab)

Participate Sites
13Sites

Terminated11Sites

2026-03-04 - 2034-03-11

Phase II/III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites